Physician

Abi Waqas, M.D.

According to 2025 Medicare claims, Abi Waqas, M.D. (NPI: 1396988168) practices internal medicine in the Flint, MI market, with the plurality of this provider's patient population coming from Genesee, MI. This provider's primary affiliated billing organization is GENESEE LUNG ASSOCIATES PC (NPI: 1922110477; TIN: 38-2635647) and primary practice location at 48439-8065. Waqas is affiliated with the Genesys PHO, L.L.C. (ACO ID: A2597), participating under the MSSP model.

Waqas' data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 591 traditional Medicare patients, billed 2,143 HCPCS/CPT codes, and received $171,484 in Medicare payments. The top billing code was 99223 (Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes). Part D data shows 1,180 prescription claims across 275 beneficiaries totaling $584,909 in drug costs, led by Trelegy Ellipta (Fluticasone/Umeclidin/Vilanter). DME data shows 382 claims. Open Payments data shows 74 records totaling $1,885. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has fallen sharply in recent years, from $112,846 to $171,484. In contrast, Part D prescription costs have moved sharply higher in recent years, from $12,661 to $584,909. For DME billing, this smaller-volume category moved sharply higher in recent years, from $4,131 to $30,529.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	499	1,416	$112,846
2016	433	1,545	$116,870
2017	395	1,442	$99,974
2018	383	1,396	$98,448
2019	233	988	$69,829
2020	56	203	$13,555
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	101	237	$18,091
2024	591	2,143	$171,484

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	123	285	$12,661
2016	154	395	$23,395
2017	179	460	$18,770
2018	157	434	$17,807
2019	143	330	$14,471
2020	67	119	$5,517
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	21	27	$4,191
2024	275	1,180	$584,909

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	39	$3,379
2016	N/R	88	$3,181
2017	N/R	69	$2,720
2018	N/R	N/R	N/R
2019	N/R	33	$1,201
2020	N/R	30	$885
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	52	$14,666
2024	123	382	$27,409

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	137	145	$132
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	126	186	$92
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	267	669	$90
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	206	542	$60
94060	Test to measure expiratory airflow and volume changes before and after medication administration	82	85	$24

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	234	11,100	$221,447
Ofev	Nintedanib Esylate	13	390	$160,844
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	79	3,330	$49,407
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	69	3,270	$23,270
Spiriva Respimat	Tiotropium Bromide	19	1,110	$18,344

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
E0466	Home ventilator, any type, used with non-invasive interface, (e.g., mask, chest shell)	Y	N/R	11	$11,044
E1390	Oxygen concentrator, single delivery port, capable of delivering 85 percent or greater oxygen concentration at the prescribed flow rate	Y	12	66	$5,085
A7030	Full face mask used with positive airway pressure device, each	N	16	25	$2,173
A7031	Face mask interface, replacement for full face mask, each	N	14	21	$1,834
E0601	Continuous positive airway pressure (cpap) device	Y	N/R	43	$1,728

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	74	$1,885	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Abi Waqas, M.D.?

Tedicare shows public-source Medicare data for Abi Waqas, M.D. (NPI 1396988168), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Abi Waqas, M.D. have ACO affiliation data?

Abi Waqas, M.D. is shown with ACO affiliation data for Genesys PHO, L.L.C. (MSSP, ACO ID A2597).

What billing organization is linked to Abi Waqas, M.D.?

Abi Waqas, M.D. is linked to GENESEE LUNG ASSOCIATES PC (billing NPI 1922110477) in the available physician profile data.

Does Abi Waqas, M.D. have Open Payments data?

Abi Waqas, M.D. has 74 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.